Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Abbott Laboratories (NYSE:ABT)

Adjustments to Financial Statements

Advanced level

Adjustments to Current Assets

Abbott Laboratories, adjusted current assets

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
As Reported
Current assets 20,441  15,667  14,632  20,147  26,776 
Adjustments
Add: Allowances for doubtful accounts 288  384  314  294  250 
After Adjustment
Adjusted current assets 20,729  16,051  14,946  20,441  27,026 

Based on: 10-K (filing date: 2021-02-19), 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17).


Adjustments to Total Assets

Abbott Laboratories, adjusted total assets

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
As Reported
Total assets 72,548  67,887  67,173  76,250  52,666 
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 —  —  871  984  674 
Add: Allowances for doubtful accounts 288  384  314  294  250 
Less: Deferred tax assets2 1,163  1,010  781  1,390  2,026 
After Adjustment
Adjusted total assets 71,673  67,261  67,577  76,138  51,564 

Based on: 10-K (filing date: 2021-02-19), 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred tax assets. See details »


Adjustments to Total Liabilities

Abbott Laboratories, adjusted total liabilities

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
As Reported
Total liabilities 39,545  36,586  36,451  45,152  31,949 
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 —  —  871  984  674 
Less: Deferred tax liabilities2 1,406  1,546  2,056  2,006  356 
Less: Restructuring Plans, accrued balance 70  125  111  141  82 
After Adjustment
Adjusted total liabilities 38,069  34,915  35,155  43,989  32,185 

Based on: 10-K (filing date: 2021-02-19), 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred tax liabilities. See details »


Adjustments to Stockholders’ Equity

Abbott Laboratories, adjusted total Abbott shareholders’ investment

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
As Reported
Total Abbott shareholders’ investment 32,784  31,088  30,524  30,897  20,538 
Adjustments
Less: Net deferred tax assets (liabilities)1 (243) (536) (1,275) (616) 1,670 
Add: Allowances for doubtful accounts 288  384  314  294  250 
Add: Restructuring Plans, accrued balance 70  125  111  141  82 
Add: Noncontrolling interests in subsidiaries 219  213  198  201  179 
After Adjustment
Adjusted total shareholders’ investment 33,604  32,346  32,422  32,149  19,379 

Based on: 10-K (filing date: 2021-02-19), 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17).

1 Net deferred tax assets (liabilities). See details »


Adjustments to Capitalization Table

Abbott Laboratories, adjusted capitalization table

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
As Reported
Short-term borrowings 213  201  200  206  1,322 
Current portion of long-term debt 1,277  508 
Long-term debt, excluding current portion 18,527  16,661  19,359  27,210  20,681 
Total reported debt 18,747  18,139  19,566  27,924  22,006 
Total Abbott shareholders’ investment 32,784  31,088  30,524  30,897  20,538 
Total reported capital 51,531  49,227  50,090  58,821  42,544 
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 —  —  871  984  674 
Add: Operating lease liability, current (included in Other accrued liabilities)2 241  205  —  —  — 
Add: Operating lease liability, non-current3 902  755  —  —  — 
Adjusted total debt 19,890  19,099  20,437  28,908  22,680 
Adjustments to Equity
Less: Net deferred tax assets (liabilities)4 (243) (536) (1,275) (616) 1,670 
Add: Allowances for doubtful accounts 288  384  314  294  250 
Add: Restructuring Plans, accrued balance 70  125  111  141  82 
Add: Noncontrolling interests in subsidiaries 219  213  198  201  179 
Adjusted total shareholders’ investment 33,604  32,346  32,422  32,149  19,379 
After Adjustment
Adjusted total capital 53,494  51,445  52,859  61,057  42,059 

Based on: 10-K (filing date: 2021-02-19), 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Operating lease liability, current (included in Other accrued liabilities). See details »

3 Operating lease liability, non-current. See details »

4 Net deferred tax assets (liabilities). See details »


Adjustments to Reported Income

Abbott Laboratories, adjusted net earnings

US$ in millions

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
As Reported
Net earnings 4,495  3,687  2,368  477  1,400 
Adjustments
Add: Deferred income tax expense (benefit)1 (108) (491) 745  (890) (127)
Add: Increase (decrease) in allowances for doubtful accounts 60  70  20  44  (87)
Add: Increase (decrease) in restructuring Plans, accrued balance (9) 14  (76) 59  (117)
Less: Net earnings from discontinued operations, net of taxes 24  —  34  124  337 
Add: Other comprehensive income (loss) (481) (879) (1,192) 1,052  (605)
After Adjustment
Adjusted net earnings 3,933  2,401  1,831  618  127 

Based on: 10-K (filing date: 2021-02-19), 10-K (filing date: 2020-02-21), 10-K (filing date: 2019-02-22), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-17).

1 Deferred income tax expense (benefit). See details »